The IFN‐γ‐CXCL9/CXCL10‐CXCR3 axis in vitiligo: Pathological mechanism and treatment
European Journal of Immunology · 2024-04 · 54 (4)
DOI: 10.1002/eji.202250281 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Immunology, online erschienen am 05.03.2024. Verfasst von Hanqing Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Precision Research Center for Refractory Diseases, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China. Hauptthemen laut MEDLINE: Vitiligo. Die Arbeit wurde bisher 89-mal zitiert (Crossref) und nennt 83 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Clinical Research Plan of Shanghai Shenkang Hospital Development Center.
Abstract (Originalsprache)
Vitiligo is a disease featuring distinct white patches that result from melanocyte destruction. The overall pathogenesis of vitiligo remains to be elucidated. Nevertheless, considerable research indicates that adaptive immune activation plays a key role in this process. Specifically, the interferon‐gamma (IFN‐γ), C‐X‐C motif chemokine ligands (CXCL9/10), and C‐X‐C motif chemokine receptor (CXCR3) signaling axis, collectively referred to as IFN‐γ‐CXCL9/10‐CXCR3 or ICC axis, has emerged as a key mediator responsible for the recruitment of autoimmune CXCR3 + CD8 + T cells. These cells serve as executioners of melanocytes by promoting their detachment and apoptosis. Moreover, IFN‐γ is generated by activated T cells to create a positive feedback loop, exacerbating the autoimmune response. This review not only delves into the mechanistic insights of the ICC axis but also explores the significant immunological effects of associated cytokines and their receptors. Additionally, the review provides a thorough comparison of existing and emerging treatment options that target the ICC axis for managing vitiligo. This review aims to foster further advancements in basic research within related fields and facilitate a deeper understanding of alternative treatment strategies targeting different elements of the axis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Precision Research Center for Refractory Diseases, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.
- College of Health Science and Technology, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.
- School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, P. R. China.
- Shanghai Institute of Immunology, Precision Research Center for Refractory Diseases, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.
ORCID-Profile: Yihui Wang, Honglin Wang
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Clinical Research Plan of Shanghai Shenkang Hospital Development Center
- Innovative Research Team of High-Level Local Universities in Shanghai
- Shanghai Committee of Science and Technology, China
- Scientific Research Project of Shanghai Municipal Commission of Health and Family Planning
Zitieren
APA
Liu, H., Wang, Y., Le, Q., Tong, J., & Wang, H. (2024). The IFN‐γ‐CXCL9/CXCL10‐CXCR3 axis in vitiligo: Pathological mechanism and treatment. European Journal of Immunology, 54(4). https://doi.org/10.1002/eji.202250281
Vancouver
Liu H, Wang Y, Le Q, Tong J, Wang H. The IFN‐γ‐CXCL9/CXCL10‐CXCR3 axis in vitiligo: Pathological mechanism and treatment. European Journal of Immunology. 2024;54(4). doi:10.1002/eji.202250281
BibTeX
@article{Liu2024,
author = {Liu, Hanqing and Wang, Yihui and Le, Qianqian and Tong, Jiajia and Wang, Honglin},
title = {The IFN‐γ‐CXCL9/CXCL10‐CXCR3 axis in vitiligo: Pathological mechanism and treatment},
journal = {European Journal of Immunology},
year = {2024},
volume = {54},
number = {4},
doi = {10.1002/eji.202250281}
}
EUVIMED